Multimodal therapy in the management of lacrimal gland adenoid cystic carcinoma

Jie Yang 1,2, Chuandi Zhou 1,2, Yefei Wang 1,2*, Xianqun Fan 1,2* and Renbing Jia 1,2*

Abstract

Background: To evaluate the prognosis of Chinese patients with lacrimal gland adenoid cystic carcinoma treated with eye-sparing surgery and adjuvant multimodal therapy.

Methods: The study included 24 consecutive patients with lacrimal gland adenoid cystic carcinoma treated at the Ninth People’s Hospital of Shanghai from May 2008 to September 2017. All patients underwent eye-sparing surgical tumor resection and 20 (83.3%) of the 24 patients in the cohort received postoperative RT. Eight (41.7%) patients in the cohort received chemotherapy. Each patient’s medical records were reviewed.

Results: The study included 13 male and 11 female patients. The median follow-up time after surgery was 33.5 months. Fifteen (62.5%) patients experienced local recurrence. The 1-, 3-, and 5-year recurrence rates were 27.9, 60.0, and 80.0%, respectively. Eleven (45.8%) patients developed metastasis. The 1-, 3-, and 5-year metastasis rates were 8.7, 48.5, and 66.9%, respectively. Eight (33.3%) patients died of lacrimal gland adenoid cystic carcinoma, with a median survival duration of 34.0 months. The 1-, 3-, and 5-year tumor-related mortality was 4.5, 28.1, and 58.0%, respectively.

More advanced T stage (≥ T3a) was a risk factor for local recurrence (hazard ratio [HR]: 5.374, P = 0.02), distant metastasis (HR: 8.585, P < 0.01), and tumor-related survival (HR: 9.654, P < 0.01).

Conclusions: Eye-sparing tumor resection protocol followed by adjuvant therapy seems to be associated with high rates of local recurrence, metastases and death. In addition, greater attention should be paid to patients with lacrimal gland adenoid cystic carcinoma with ≥ T3a tumors.

Keywords: Lacrimal gland adenoid cystic carcinoma, Eye-sparing surgery, Local recurrence, Metastasis, Tumor-related mortality, 8th American joint committee on Cancer

Background

Lacrimal gland adenoid cystic carcinoma (LGACC) accounts for 25–40% of all epithelial tumors of the lacrimal gland [1]. In China, adenoid cystic carcinoma (20.0%) is one of the most common epithelial tumors of the lacrimal gland [2]. In addition, Lacrimal gland adenoid cystic carcinoma has an aggressive behavior and is associated with significant morbidity and mortality [3, 4].

In the literature, the overall tumor-related mortality of LGACC is 10–87% [5–13]. LGACC exhibits local recurrence and unfavorable outcomes even when managed with aggressive local treatment [7, 14–20].

The different therapeutic options for LGACC have been described by institution. The traditional surgical treatment is orbital exenteration. Orbital exenteration followed by radiotherapy has been widely used for lacrimal gland carcinoma without distant metastasis [21]. For adjuvant radiation therapy, various types have been reported, including external-beam radiation therapy, proton therapy, and brachytherapy [6–8, 22–26]. However, in recent articles, radical surgical treatment did not improve the overall survival outcomes of patients with LGACC [5, 27]. In addition, studies have demonstrated that the quality of life of patients who underwent orbital exenteration is markedly reduced [28]. In 2013, one excellent study by Tse and colleagues clarified neoadjuvant intra-arterial cytoreductive chemotherapy (IACC) may improve overall survival and decrease disease recurrence. Furthermore, the chemo-toxicity complication rate is limited and manageable [7].
In the past decade, our institution has performed eye-sparing surgery in patients with lacrimal gland adenoid cystic carcinoma (Fig. 1). In this report, we evaluated the outcomes, including local recurrence, distant metastases, and survival after eye-sparing surgery, for LGACC in Chinese patients and explore the prognostic factors for local recurrence and metastasis.

**Methods**

**Patients**

All consecutive patients of LGACC who were treated with eye sparing surgery between May 2008 and September 2017 at the Ninth People’s Hospital of Shanghai were retrospectively reviewed. The therapy sequence is surgery, then RT and intravenous chemotherapy last. The recurrence cases were given the same modality of treatment. The exclusion criteria were as follows: (1) incomplete available clinical data and (2) a follow-up period of < 3 months. We contacted all patients who were eligible for inclusion or their relatives, which were legal guardians. We explained the purpose of our study, and the patients all volunteered to participate in this study. Informed consent in verbal form was obtained from all patients or their relatives at the follow-up visit. This study adhered to the tenets of the Declaration of Helsinki and was approved by the Shanghai JiaoTong University research ethics committee.

**Data collection**

The patients’ clinical information included age, sex, duration of symptoms, greatest basal diameter of tumor, presence of perineural invasion, findings on imaging studies (magnetic resonance imaging (MRI) or computed tomography (CT)), the presence of adjuvant treatments and 8th AJCC stage at presentation to our hospital. The main outcome measures were local recurrence, distant metastasis, death due to disease or unrelated causes, and the time from surgery of each event. The local recurrence and distant metastasis confirmed by MRI or CT scanning.

**Statistical analysis**

All data were processed using the Statistical Package for the Social Sciences software package, version 23.0 (SPSS, Chicago, IL). First, we used univariate Cox proportional hazards regression to identify possible factors associated with recurrence, metastasis, and tumor-related death. Regression coefficients and hazard ratios (HRs) with 95% confidence intervals were calculated. The Kaplan-Meier method was used to analyze the local recurrence, metastasis, and tumor-related death rates. In addition, the log-rank test was used to compare the overall survival of patients with < T3a and ≥ T3a primary tumors. All tests were 2-sided, and a P value of < 0.05 was considered statistically significant.

**Results**

**Clinical data**

A total of 24 patients were recruited in this study; 13 (54.2%) were male, and 11 (45.8%) were female (Table 1). The age of the patients ranged from 32.0 to 83.0 years, with a median of 54.0 years. Treatment before referral to our hospital was noted in 5 (20.8%) patients. They were received a biopsy and eye-sparing surgical tumor resection. Primary symptoms included exophthalmos (7, 29.2%), orbital pruritus (1, 4.2%), a mass noted on imaging studies (5, 20.8%), eyeball displacement (2, 8.3%), tearing (1, 4.2%), ptosis of the upper eyelid (1, 4.2%), pain (5, 20.8%), and decreased vision (2, 8.3%). The median duration of symptoms was 6.0 months (range: 1.0–120.0 months). The median tumor dimension was 26.5 mm (range: 12.0–55.0 mm). At the time of initial diagnosis, one (4.2%) patient (case 10) had distant metastasis in the brain, confirmed by CT scanning.
The distribution of tumor histologic subtypes of 21 (87.5%) patients were collected (Fig. 2). It is summarized as follows: predominantly basaloid (solid), 2 (9.5%) patients; predominantly cribriform, 13 (61.9%) patients; mixed, 6 (28.6%) patients; and tubular, 0 patient. Additionally, 13 (51.2%) patients had perineural invasion based on histologic evidence.

Preoperative imaging findings were available for 20 (83.3%) patients. Four other patients received CT scans in the outer hospital and data failure. Of these, 14 (70.0%) patients had CT or MRI evidence of bone involvement.

American joint committee on Cancer classification at initial diagnosis
The 8th AJCC classification for LGACC at initial diagnosis for the 24 patients was as follows: T1aN0M0, 6 (25.0%) patients; T1bN0M0, 1 (4.2%) patient; T2aN0M0, 5 (20.9%) patients; T2bN0M0, 8 (33.3%) patients; T3bN0M0, 3 (12.5%) patients; and T4cN0M1, 1 (4.2%) patient (Table 1). Four (16.7%) of the 24 patients had ≥ T3a tumors at presentation.

Treatment modalities
All (100.0%) patients received eye-preserving surgery. And if the patients’ preoperative imaging suggested bony involvement, the affected orbital bone will be removed. If not, performed gross total resection of the lacrimal gland mass. Overall, 20 (83.3%) of the 24 patients in the cohort received postoperative RT, and no one discontinued treatment because of complications. In addition, 4 patients did not receive postoperative adjuvant therapy because they refused. Eight (41.7%) patients in the cohort received chemotherapy.

Outcome
The median follow-up period was 33.5 months (range: 3.0–113.0 months). During the follow-up, 15 (62.5%) patients had local recurrence; among them, eight (33.3%) patients experienced recurrence within the first year after initial diagnosis. Five (20.8%) patients had more than two recurrences. The median duration to the initial recurrence was 16.0 months (mean: 23.3 ± 16.1 months;
range: 4.0–58.0 months). By Kaplan-Meier survival estimates, the 1-, 3-, and 5-year recurrence rates were 27.9, 60.0, and 80.0%, respectively.

In this study, 11 (45.8%) patients developed metastasis. The initial metastasis locations included the cervical lymph nodes (1, 5.2%), brain (7, 29.2%), liver (1, 5.2%), lung (4, 16.7%), and nose (1, 5.2%). Among these patients, three (12.5%) presented with metastases involving multiple sites. The median duration between the initial diagnosis and first metastasis was 25.0 months (mean: 28.4 ± 17.1 months; range: 4.0–68.0 months). By Kaplan-Meier survival estimates, the 1-, 3-, and 5-year metastasis rates were 8.7, 48.5, and 66.9%, respectively.

During follow-up, 8 (33.3%) patients died of distant metastasis from LGACC, with a median survival time of 34.0 months (mean: 35.6 ± 21.2 months; range: 5.0–74.0 months). By Kaplan-Meier survival estimates, the 1-, 3-, and 5-year tumor-related mortality was 4.5, 28.1, and 58.0%, respectively.

Univariate Cox analysis (Table 2) indicated that tumor diameter is a risk factor for recurrence (HR: 4.573, \( P = 0.032 \)), metastasis (HR: 4.024, \( P = 0.045 \)), and tumor-related survival (HR: 8.125, \( P < 0.01 \)).

According to the 8th edition of the AJCC classification for LGACC, we stratified all patients into 2 groups by their clinicopathologic characteristics. In our study, all patients with \( \geq T3a \) tumors experienced local recurrence, distant metastasis and died of the disease. In contrast, 11 (55.5%) of 20 (83.3%) patients with \(< T3a \) tumors experienced local recurrence, 7 (35.0%) experienced distant metastasis, and 4 (20.0%) died of the disease. Thus, the incidence of poor outcomes is much higher in patients with \( \geq T3a \) tumors than in patients with \(< T3a \) tumors.

The Kaplan-Meier recurrence-free survival, metastasis-free survival and tumor-related survival curves of patients with \( \geq T3a \) tumors and \(< T3a \) tumors are shown in Fig. 3. The rates of local recurrence, metastasis and death were significantly different between patients with \( \geq T3a \) tumors and patients with \(< T3a \) tumors (all \( P < 0.05 \)).

**Discussion**

Based on our observation, \( \geq T3a \) tumors according to the 8th AJCC classification at initial diagnosis were related to poor outcomes. Univariate Cox analysis showed an association with recurrence, metastasis and tumor-related survival. These results are consistent with the findings of Ahmad et al. The authors indicated that \( \geq T3 \) tumors at initial diagnosis were related to poor outcomes. Overall survival was worse, and time to metastasis was significantly shorter for patients with \( \geq T3a \) tumors than for patients with \(< T3a \) tumors [14].

Based on published cases in the rest of the world, the exhibited recurrence rates are America (9.1% [5], 0.0% [6], 15.8% [7], 16.7% [8], 44.6% [9], 35.0% [10], and 16.7% [11]), India (10.0% [12]), and Japan (50.0% [13]); and tumor-related death rates are America (0.0% [5],
Table 2 Univariate analyses of clinical characteristics for tumor-related death, metastasis, and local recurrence in Chinese patients with lacrimal gland adenoid cystic carcinoma

| Characteristics | Total | Recurrence (+) | Recurrence (−) | P | Metastasis (+) | Metastasis (−) | P | Tumor-related death (+) | Tumor-related death (−) | P |
|-----------------|-------|----------------|--------------|---|---------------|---------------|---|----------------------|----------------------|---|
| Sex             | 24    | 0.668          | 0.818        | 0.540 | 0.608         | 0.781         | 0.527 | 0.540                | 0.462                | 0.13 |
| Male, no. (%)   | 13 (54.2) | 9 (60.0) | 4 (44.4) | 6 (54.5) | 7 (53.8) | 5 (62.5) | 8 (50.0) |
| Female, no. (%) | 11 (45.8) | 6 (40.0) | 5 (55.6) | 5 (45.5) | 6 (41.2) | 3 (37.5) | 8 (50.0) |
| Age y           | 53.2 ± 12.9 | 52.2 ± 14.8 | 54.9 ± 9.4 | 0.901 | 54.8 ± 15.9 | 51.9 ± 10.2 | 0.407 | 51.1 ± 16.2 | 54.3 ± 11.3 | 0.990 |
| Affected Side   | 24    | 0.740          | 0.979        | 0.398 | 0.319         | 0.626         | 0.894 |         |         |   |
| Right, no. (%)  | 10 (41.7) | 7 (46.7) | 3 (33.3) | 5 (45.5) | 5 (38.5) | 5 (62.5) | 5 (31.3) |
| Lift, no. (%)   | 14 (58.3) | 8 (53.3) | 6 (66.7) | 6 (54.5) | 8 (61.5) | 3 (37.5) | 11 (68.7) |
| RT              | Yes, no. (%) | 20 (83.3) | 12 (80.0) | 8 (88.9) | 10 (90.9) | 10 (76.9) | 7 (87.5) | 13 (81.3) |
| No, no. (%)     | 4 (16.7) | 3 (20.0) | 1 (11.1) | 1 (9.1) | 3 (23.1) | 1 (12.5) | 3 (18.7) |
| CT              | Yes, no. (%) | 10 | 7 (46.7) | 3 (33.3) | 6 (54.5) | 4 (30.8) | 4 (50.0) | 6 (37.5) |
| No, no. (%)     | 14 | 8 (53.3) | 6 (66.7) | 5 (45.5) | 9 (69.2) | 4 (50.0) | 10 (62.5) |
| diameter mm     | 29.1 ± 11.0 | 32.0 ± 123 | 24.3 ± 64 | 0.032 * | 33.0 ± 13.4 | 25.8 ± 7.6 | 0.045 * | 38.3 ± 11.5 | 24.6 ± 7.6 | 0.004 * |
| PNI             | Yes, no. (%) | 13 | 9 (60.0) | 4 (44.4) | 6 (54.5) | 7 (53.8) | 5 (62.5) | 8 (50.0) |
| No, no. (%)     | 11 | 6 (40.0) | 5 (55.6) | 5 (45.5) | 6 (41.2) | 3 (37.5) | 8 (50.0) |

PNI = perineural invasion; RT = postoperative radiation therapy; CT = Chemotherapy

71.4% [6], 84.2% [7], 38.9% [8], 34.4% [9], 65.0% [10], and 44.4% [11]), and Japan (30.0% [13]). Our findings indicated that 15 (62.5%) patients experienced local recurrence, and 8 (33.3%) patients died of distant metastasis. Based on worldwide data, the recurrence rate in our study was in the higher end of the range, and the tumor-related death rate was comparable to international reports. The reasons were possibly as follows: 1. the histologic subtypes are different. Prior studies showed the basaloid histologic subtype has been suggested to be related with poor outcomes in patients, and in this study, the patients had no basaloid histologic subtype; 2. different doctors’ surgical techniques and methods are different.

Worldwide, there is no agreement regarding the standard for optimal surgery for LGACC [10, 14, 23]. Developing effective treatments for LGACC is especially difficult for at least the following reasons: 1. the incidence of LGACC is very low [29]; 2. because of the complicated structure of the eye, development of new methods has been particularly challenging for ophthalmologists; and 3. the time between initial diagnosis and death is long [30].

Appropriate local treatment for LGACC remains controversial [6, 8]. Historically, orbital exenteration has been the most common surgery for lacrimal gland carcinoma [5, 30]. However, the radical surgical approach did not seem to reduce the patient’s rates of recurrence, metastasis and mortality [6, 10] but reduced the patient’s quality of life because of functional disability and disfigurement [30, 31]. Esmaeli et al. reported favorable outcomes of eye-sparing tumor excision combined with adjuvant RT or chemo-radiotherapy for 11 patients with lacrimal gland carcinoma. Seven patients were diagnosed with LGACC. In their study, all 11 patients were free of disease at last contact [5]. Recently, Jisang Han’s team presented their results. Nine of 10 patients in their cohort did not experience any local recurrence, and the remaining patient with local recurrence was successfully treated with orbital exenteration. The authors also think that eye-sparing surgery followed by adjuvant RT should be considered [31]. And also, eye-sparing surgery with high-dose proton beam radiation provides a variable period of useful vision, and has a nice long-term survival [32]. However, our patients are related to high rates of local recurrence, metastases and death. This may be should consider perineural invasion and subclinical metastases.

Differences were determined based on whether the patients received postoperative adjuvant therapy. Ahmad et al. observed that among patients with ≥ T3 tumors, the risk of local recurrence was increased in patients who did not receive postoperative RT [14]. According to our findings, compared with 12 (60.0%) of 20 patients who were treated with postoperative RT, three (75.0%) of the 4 patients who were not treated with postoperative adjuvant
Fig. 3 The presence of T3a stage and prognosis in Chinese patients with lacrimal gland adenoid cystic carcinoma. Significantly lower recurrence-free (a), metastasis-free (b) and tumor-related (c) survival rates were observed in patients with < T3a and ≥ T3a tumors according to the 8th AJCC classification (all P < 0.05).
therapy had local recurrence. However, 7 of 10 (70%) patients who received concurrent chemo-radiotherapy, also had local recurrence. Ten patients received postoperative RT only, and 5 (50.0%) had local recurrence. According to these observations, in patients with LGACC, because of eye-sparing surgery, small lesion residue will lead to high recurrence rate, the mortality did not increase.

However, in our study, perineural invasion, which has been previously reported as an independent risk factor [19, 33], had no significant correlation with tumor local recurrence, metastasis or death ($P > 0.05$). The reason may be the relatively small sample size of our study.

While multivariate analysis based on this small cohort would be challenging, obtaining statistically significant conclusions is difficult. However, importantly, this study is the first evaluation comparing detailed clinical characteristics and outcomes in Chinese patients with LGACC and one of largest series of patients with eye-sparing surgery of LGACC reported to date. A previous published report suggested that eye-preserving surgery followed by RT is appropriate only for patients with $< T3$ tumors, whereas patients with $\geq T3$ tumors should be treated with orbital exenteration with bone removal and RT [14]. However, that report was based on the 6th edition of AJCC criteria which was very different from the 8th edition. Therefore, our findings are not comparable to the results observed by Woo et al. [27], Esmaeli et al. [5] and Han et al. [31]. Future studies comparing eye-sparing surgery with orbital exenteration for LGACC are needed to validate the effectiveness and safety of eye-sparing surgery in patients who are treated with adjuvant treatments.

Conclusions
Eye-sparing tumor resection protocol followed by adjuvant therapy seems to be associated with high rates of local recurrence, metastases and death. In addition, greater attention should be paid to patients with lacrimal gland adenoid cystic carcinoma with $\geq T3a$ tumors.

Abbreviations
AJCC: American Joint Committee on Cancer; CT: Chemotherapy; CT: Computed tomography; LGACC: Lacrimal gland adenoid cystic carcinoma; MRI: Magnetic resonance imaging; PNI: Perineural invasion; RT: Postoperative radiation therapy

Acknowledgements
Thank Bita Esmaeili for critical appraisal and revision of the manuscript.

Funding
This clinical study was supported by the National Natural Science Foundation of China to RENBING JIA (81570884, 81770961). These funding provided support in the design of the study and collection, analysis, interpretation of data, and professional English-language editing of the manuscript.

Availability of data and materials
The datasets used and analyzed during the current study available from the corresponding author on reasonable request.

Authors’ contributions
RBJ, XQF and YFW conceived the study, coordinated its design. JY wrote the paper. CDZ provided statistical expertise. All authors read and approved the final manuscript.

Ethics approval and consent to participate
The Shanghai JiaoTong University research ethics committee approved the study. Informed consent in verbal form was obtained from all patients or their relatives at the follow-up visit.

Consent for publication
Not applicable for this study.

Competing interests
All authors declare that they have no competing interests.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Author details
1Department of Ophthalmology, Ninth People’s Hospital, Shanghai Jiao Tong University School of Medicine, 639 Zhi Zao Ju Road, Shanghai 200011, China. 2Shanghai Key Laboratory of Orbital Diseases and Ocular Oncology, Shanghai, China.

Received: 21 September 2018 Accepted: 22 April 2019
Published online: 08 June 2019

References
1. Tellado MV, McLean IW, Specht CS, Varga J. Adenoid cystic carcinomas of the lacrimal gland in childhood and adolescence. Ophthalmology. 1997; 104(10):1622–5.
2. Zeng J, Shi JT, Li B, Sun XL, An YZ, Li LQ, Gao F, Xu JP, Jonas JB. Epithelial tumors of the lacrimal gland in the Chinese: a clinicopathologic study of 298 patients. Graefes Arch Clin Exp Ophthalmol. 2010;248(9):1345–9.
3. Sanders JC, Mendenhall WM, Wening JW. Adenoid cystic carcinoma of the lacrimal gland. Am J Otolaryngol. 2016;37(2):144–7.
4. Ducrey NVJ, Jaques B. Cystic adenocarcinomas of the lacrimal gland. Klin Monatsbl Augenheilkd. 2002;219(4):231–4.
5. Esmaeili B, Yin VT, Hanna EY, Kies MS, William WN Jr, Bell D, Frank SJ. Eye-sparing multidisciplinary approach for the management of lacrimal gland carcinoma. Head Neck. 2016;38(8):1258–62.
6. Esmaeili B, Golio D, Kies M, DeMonte F. Surgical management of locally advanced adenoid cystic carcinoma of the lacrimal gland. Ophthalmic Plast Reconstr Surg. 2006;22(5):366–70.
7. Tse DT, Kossler AL, Feuer WJ, Benedetto PW. Long-term outcomes of neoadjuvant intra-arterial cytoreductive chemotherapy for lacrimal gland adenoid cystic carcinoma. Ophthalmology. 2013;120(7):1313–23.
8. Williams MD, Al-Zubidi N, Debnam JM, Shinder R, DeMonte F, Esmaeili B. Bone invasion by adenoid cystic carcinoma of the lacrimal gland: preoperative imaging assessment and surgical considerations. Ophthal Plast Reconstr Surg. 2010;26(6):403–8.
9. Tse DT, Benedetto P, Dubovy S, Schiffman JC, Feuer WJ. Clinical analysis of the effect of intraarterial cytoreductive chemotherapy in the treatment of lacrimal gland adenoid cystic carcinoma. Am J Ophthalmol. 2006;141(1):44–53.
10. Bita Esmaeili MAA, Yousuff A, Diba R, Amato M, Myers JN, Kies M, El-Naggar A. Outcomes in patients with adenoid cystic carcinoma of the lacrimal gland. Ophthal Plast Reconstr Surg. 2004;20(2):22–6.
11. El-Sawy TSA, Williams MD. Prognostic accuracy of the seventh edition vs sixth edition of the American joint committee on Cancer tumor classification for adenoid cystic carcinoma of the lacrimal gland. Arch Ophthalmol. 2012;130(5):664–6.
12. Roshan V, Pathy S, Mallick S, Chander S, Sen S, Chawla B. Adjuvant radiotherapy with three-dimensional conformal radiotherapy of lacrimal gland adenoid cystic carcinoma. J Clin Diagn Res. 2015;9(10):XC05–7.
13. Ueda SGH, Matsubayashi J, Nagao T. Adenoid cystic carcinoma of the lacrimal gland: clinicopathological study. Nippon Ganka Gakkai Zasshi. 2014;118(1):963–7.
14. Ahmad SM, Esmaeili B, Williams M, Nguyen J, Fay A, Woog J, Selvadurai D, Rootman J, Weis E, Selva D, et al. American joint committee on Cancer...
classification predicts outcome of patients with lacrimal gland adenoid cystic carcinoma. Ophthalmology. 2009;116(6):1210–5.
15. Lee DA, Campbell RJ, Waller RR, Ilstrup DM. A clinicopathologic study of primary adenoid cystic carcinoma of the lacrimal gland. Ophthalmology. 1985;92(1):128–34.
16. Byars RL, SLSRG. Malignant epithelial tumors of the lacrimal gland: a clinicopathologic study of 21 cases. Arch Ophthalmol. 1998;116(5):613–6.
17. Byers RM, Berkeley RG, Luna M, Jesse RH. Combined therapeutic approach to malignant lacrimal gland tumors. Am J Ophthalmol. 1975;79(1):53–5.
18. Wright JESW, Krohel GB. Clinical presentation and management of lacrimal gland tumours. Br J Ophthalmol. 1979;63(9):600–6.
19. John W, Gannel RLF. adenoid cystic carcinoma of the lacrimal gland: the clinical significance of a basaloid histologic pattern. Hum Pathol. 1982;13(3):219–25.
20. Wright JE. Factors affecting the survival of patients with lacrimal gland tumours. Canadian journal of ophthalmology. Journal canadien d'ophthalmologie. 1982;17(1):3–9.
21. Woo KI, Kim YD, Sa HS, Esmaeli B. Current treatment of lacrimal gland carcinoma. Curr Opin Ophthalmol. 2016;27(5):449–56.
22. Meldrum ML, Tse DT, Benedetto P. Neoadjuvant intracarotid chemotherapy for treatment of advanced adenocystic carcinoma of the lacrimal gland. Arch Ophthalmol. 1998;116(3):315–21.
23. Shields JA, Shields CL, Freire JE, Brady LW, Komarnicky L. Plaque radiotherapy for selected orbital malignancies: preliminary observations: the 2002 Montgomery lecture, part 2. Ophthalmic Plast Reconstr Surg. 2003;19(2):91–5.
24. Douglas JG, Laramore GE, Austin-Seymour M, Koh W, Stelzer K, Griffin TW. Treatment of locally advanced adenoid cystic carcinoma of the head and neck with neutron radiotherapy. Int J Radiat Oncol Biol Phys. 2000;46(3):511–7.
25. Sidrys LA, Fritz KJ, Varjakojis D. Fast neutron therapy for orbital adenoid cystic carcinoma. Ann Ophthalmol. 1982;14(4):42–5.
26. Buchholz TA, Shimotakahara SG, Weymuller EA Jr, Laramore GE, Griffin TW. Neutron radiotherapy for adenoid cystic carcinoma of the head and neck. Archives of otolaryngology–head & neck surgery. 1993;119(7):747–52.
27. Woo KI, Sagiv O, Han J, Frank SJ, Kim YD, Esmaeli B. Eye-preserving surgery followed by adjuvant radiotherapy for lacrimal gland carcinoma: outcomes in 37 patients. Ophthalmic Plast Reconstr Surg. 2018.
28. Bonanno A, Esmaeli B, Fingeret MC, Nelson DV, Weber RS. Social challenges of cancer patients with orbitofacial disfigurement. Ophthalmic Plast Reconstr Surg. 2010;26(1):18–22.
29. Li N, Xu L, Zhao H, El-Naggar AK, Sturgis EM. A comparison of the demographics, clinical features, and survival of patients with adenoid cystic carcinoma of major and minor salivary glands versus less common sites within the surveillance, epidemiology, and end results registry. Cancer. 2012;118(16):3945–53.
30. Bradley EA, Bradley DJ. Adenoid cystic carcinoma of the lacrimal gland: rare ... Lethal ... Cured? Ophthalmology. 2013;120(7):1311–2.
31. Han J, Kim YD, Woo KI, Sobti D. Long-term outcomes of eye-sparing surgery for adenoid cystic carcinoma of lacrimal gland. Ophthalmic Plast Reconstr Surg. 2018;34(1):74–8.
32. Wolowik N, Jakobič RA, Lee H, Sutula FC. Long-term outcomes of globe-preserving surgery with proton beam radiation for adenoid cystic carcinoma of the lacrimal gland. Am J Ophthalmol. 2018;155:43–62.
33. Garden AS, Weber RS, Morrison WH, Ang KK, Peters LJ. The influence of positive margins and nerve invasion in adenoid cystic carcinoma of the head and neck treated with surgery and radiation. Int J Radiat Oncol Biol Phys. 1995;32(3):619–26.